You are Not Enrolled in this Course.
New clinical classification of MDS, as well as the evaluation of the implications of molecular mutations, have generated valuable advances for aiding management of patients with this disease. These recent findings will be discussed during this program. The unique nature of treatment-related MDS as a specific subset of MDS will be also be reviewed. Given the understanding of immunologic abnormalities in MDS, therapeutic interventions using immune checkpoint inhibitors and T-cell based therapies will add to this discussion, as will a number of the novel treatments using biologic targeted approaches for anemias and higher risk patients.
This activity is intended for physicians, oncology nurses, nurse practitioners, physician assistants, pharmacists and other health care professionals interested in the treatment and management of patients with Myelodysplastic Syndromes.
For CME/CE information and a complete description of the program, click here.